Clinical Trial Results:
A Phase IIb, multi-center, international, double-blind, randomized, placebo-controlled, parallel-group, dose-finding study for the prevention of cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH) by intravenous administration of clazosentan, a selective endothelin A (ETA) receptor antagonist.
Summary
|
|
EudraCT number |
2004-002453-31 |
Trial protocol |
AT SE FI DE IT BE |
Global completion date |
30 Mar 2006
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
02 Dec 2016
|
First version publication date |
02 Dec 2016
|
Other versions |
|
Summary report(s) |
CSR Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.